Prab: CSV import

2024-03-06T04:06:07Z

CSV import

New page

[[File:Cilomilast.png|thumb|{{PAGENAME}}]]<br>'''Cilomilast''' is a selective [[Phosphodiesterase-4 inhibitor|PDE4 inhibitor]] developed for treating [[respiratory diseases]] such as [[chronic obstructive pulmonary disease (COPD)|COPD]] and [[asthma]]. It was developed by [[GlaxoSmithKline]] (GSK) and first approved in the [[United States]] by the [[Food and Drug Administration|FDA]] in 2004.

== Mechanism of Action ==

Cilomilast works by inhibiting the action of [[phosphodiesterase 4 (PDE4)]], an enzyme that breaks down [[cyclic adenosine monophosphate (cAMP)]]. By preventing the breakdown of cAMP, Cilomilast helps to reduce inflammation and relax the muscles of the airways, thereby improving breathing in patients with respiratory diseases.

== Clinical Use ==

Cilomilast is used primarily in the treatment of COPD, a progressive disease that makes it hard to breathe. It can also be used in the treatment of asthma, although it is not a first-line treatment for this condition. The drug is taken orally, usually once or twice a day.

== Side Effects ==

Like all medications, Cilomilast can cause side effects. The most common side effects include [[nausea]], [[diarrhea]], and [[headache]]. In rare cases, it can cause more serious side effects such as [[weight loss]], [[insomnia]], and [[depression]].

== Development and Approval ==

Cilomilast was developed by GSK and first approved by the FDA in 2004. It is marketed under the brand name Ariflo. Despite its approval, the drug has not been widely used due to its side effects and the availability of other, more effective treatments for COPD and asthma.

== See Also ==

* [[Phosphodiesterase 4]]
* [[Chronic obstructive pulmonary disease]]
* [[Asthma]]
* [[GlaxoSmithKline]]

[[Category:Drugs]]
[[Category:Respiratory system]]
[[Category:Pharmacology]]
{{Pharmacology-stub}}

Cilomilast - Revision history

Prab: CSV import